Back to top
more

GSK PLC Sponsored ADR (GSK)

(Delayed Data from NYSE)

$38.96 USD

38.96
4,990,122

-0.25 (-0.64%)

Updated Oct 17, 2024 04:00 PM ET

After-Market: $38.98 +0.02 (0.05%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value C Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 37% (93 out of 250)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Novartis (NVS) Q4 Earnings Miss Estimates, Revenues Up Y/Y

Novartis (NVS) misses estimates in Q4 as generic unit continues to face challenging business conditions. The outlook for 2019 didn't impress investors either.

Merck's Pneumococcal Vaccine Gets Breakthrough Therapy Status

Merck's (MRK) investigational pneumococcal vaccine V114 gets FDA's Breakthrough Therapy designation for prevention of invasive pneumococcal disease.

Pfizer (PFE) Q4 Earnings Beat, 2019 View Tepid, Stock Dips

Pfizer's (PFE) fourth-quarter earnings and sales beat estimates. Its forecast for 2019 falls short of expectations. Stock dips 2% in pre-market trading.

Merck (MRK) Q4 Earnings Coming Up: What's in the Cards?

Merck's (MRK) relatively newer products like Keytruda, Gardasil and Bridion are likely to drive fourth-quarter sales. However, genericization of key drugs and increasing competition are concerns.

Clovis' Rubraca Gets Nod as Maintenance Therapy in Europe

Clovis Oncology (CLVS) announces approval of label expansion for Rubraca to include maintenance treatment of ovarian cancer patients in second-line setting in Europe. Shares up.

Sanghamitra Saha headshot

What's Behind the Biotech ETF Rally to Start 2019?

Biotech ETFs have been riding on the wave of mergers and acquisitions as well as drug approvals.

Why Should You Hold Genpact (G) Stock in Your Portfolio?

Strong domain expertise in business analytics, digital and consulting services to boost demand for Genpact's (G) offerings.

Pharma Stock Roundup: Lilly to Buy Loxo for $8B, M&A in Focus at JP Morgan Meet

Lilly (LLY) is spending $8 billion to buy small cancer biotech Loxo Oncology. Big Pharma CEOs hint at spur in M&A activity in 2019.

New Strong Sell Stocks for January 11th

Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today:

Kinjel Shah headshot

4 Pharma & Biotech Pipeline Areas to Keep an Eye on in 2019

Here we present four therapeutic areas whose pipeline developments are expected to garner a lot of interest in 2019.

Big Pharma CEOs Indicate More M&A Deals at JP Morgan Meeting

Big pharma CEOs hint at spur in M&A activity in 2019 at the 37th J.P. Morgan Healthcare Conference.

The Zacks Analyst Blog Highlights: Bristol-Myers, Celgene, Lilly and Glaxo

The Zacks Analyst Blog Highlights: Bristol-Myers, Celgene, Lilly and Glaxo

Emergent (EBS) Up on '19 View, Posts Preliminary '18 Results

Emergent (EBS) provides preliminary results for 2018 and guidance for 2019. The results exceed estimates.

Crowded Cancer Space Triggers Big M&A Deals: More in Store?

Following two blockbuster merger and acquisition deals, a rise in M&A activity in the pharma space is likely led by consolidation in the cancer space.

Merck Buys NASH Candidate, Keytruda Wins 5 Approvals in Japan

Merck (MRK) exercises option to in-license an insulin sensitizer from NGM Biopharmaceuticals for NASH and type II diabetes. Its key drug Keytruda snaps up five new label expansion nods in Japan.

The Zacks Analyst Blog Highlights: Facebook, Wells Fargo, AT&T, Intel and Glaxo

The Zacks Analyst Blog Highlights: Facebook, Wells Fargo, AT&T, Intel and Glaxo

Mark Vickery headshot

Top Research Reports for Facebook, Wells Fargo & AT&T

Today's Research Daily features new research reports on 16 major stocks, including Facebook (FB), Wells Fargo (WFC) and AT&T (T).

Novartis (NVS) Benefits From New Drugs & Key Acquisitions

Novartis (NVS) gets a boost from strong performance of new drugs. Strategic acquisitions to foray into promising areas has also boosted investor sentiment.

Emergent (EBS) Files Application for Emergency Use of NuThrax

Emergent (EBS) submits an application to the FDA for the emergency use of its anthrax vaccine candidate, NuThrax.

GlaxoSmithKline (GSK) Stock Moves -0.84%: What You Should Know

In the latest trading session, GlaxoSmithKline (GSK) closed at $37.58, marking a -0.84% move from the previous day.

Pharma Stock Roundup: GSK, PFE Ink Consumer Health JV, JNJ Hit by Talc Allegations

Glaxo (GSK) and Pfizer (PFE) agree to merge their consumer healthcare units into a new JV. J&J stock hit by reports alleging it of being aware of the presence of asbestos in baby powder.

Merck's sBLA for Keytruda in Lung Cancer Gets Extended Review

FDA extends review period for label expansion application for Merck's (MRK) Keytruda in first-line lung cancer by three months. A decision is now expected in April 2019.

Novartis (NVS) Offers to Buy French Gene Therapy Manufacturer

Novartis (NVS) looks to buy French company, CellforCure to expand manufacturing capacity for innovative cell and gene therapies.

Company News For Dec 20, 2018

Companies In The News Are: FDX,GIS,LLY,PFE,GSK